CATAPRES-TTS-1 Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Catapres-tts-1, and what generic alternatives are available?

Catapres-tts-1 is a drug marketed by Lavipharm and is included in one NDA.

The generic ingredient in CATAPRES-TTS-1 is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Catapres-tts-1

A generic version of CATAPRES-TTS-1 was approved as clonidine by DIFGEN PHARMS on August 18^th, 2009.

Subscribe

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for CATAPRES-TTS-1?
What are the global sales for CATAPRES-TTS-1?
What is Average Wholesale Price for CATAPRES-TTS-1?

Summary for CATAPRES-TTS-1

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	19
Patent Applications:	7,046
What excipients (inactive ingredients) are in CATAPRES-TTS-1?	CATAPRES-TTS-1 excipients list
DailyMed Link:	CATAPRES-TTS-1 at DailyMed

Drug patent expirations by year for CATAPRES-TTS-1

Recent Clinical Trials for CATAPRES-TTS-1

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rigshospitalet, Denmark	Phase 2/Phase 3
Deventer Ziekenhuis	Phase 3
The University of Queensland	Phase 3

See all CATAPRES-TTS-1 clinical trials

Pharmacology for CATAPRES-TTS-1

Drug Class	Central alpha-2 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha2-Agonists

US Patents and Regulatory Information for CATAPRES-TTS-1

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for CATAPRES-TTS-1

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	4,559,222	⤷ Subscribe
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	3,454,701	⤷ Subscribe
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	4,201,211	⤷ Subscribe
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	4,060,084	⤷ Subscribe
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	3,996,934	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for CATAPRES-TTS-1

See the table below for patents covering CATAPRES-TTS-1 around the world.

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
Finland	42564		⤷ Subscribe
South Korea	840009035		⤷ Subscribe
Spain	532228		⤷ Subscribe
Norway	772955		⤷ Subscribe
Japan	S6214526		⤷ Subscribe
Japan	H0460091		⤷ Subscribe
Denmark	117000		⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for CATAPRES-TTS-1

Recent Clinical Trials for CATAPRES-TTS-1

Pharmacology for CATAPRES-TTS-1

Make Better Decisions: Try a trial or see plans & pricing